Paclitaxel-Coated or Uncoated Devices: Significant Differences in Patient Populations and Mortality Led to Study Incomparability

Chenyang Zhang and Guosheng Yin

Authors' affiliations:

Department of Statistics and Actuarial Science, University of Hong Kong, Hong Kong

Corresponding author:

Guosheng Yin, PhD

Patrick S C Poon Endowed Professor and Head

Department of Statistics and Actuarial Science

The University of Hong Kong

Pokfulam Road, Hong Kong SAR, China

Email: gyin@hku.hk

Tel: 852-3917-8313; Fax: 852-2858-9041

Conflicts of interest: The authors declare no potential conflict of interest.

1 Abstract

2 The SWEDEPAD trial reported an unplanned interim analysis to show no difference in
3 the mortality rate between the paclitaxel-coated and uncoated groups (Nordanstig et al.,
4 2020), which contradicts the long-term risk of paclitaxel-coated devices claimed by a
5 meta-analysis (Katsanos et al., 2018). However, there existed significant differences in
6 mortality rates between the SWEDEPAD trial and the trials included in the meta-analysis,
7 which were caused by significant differences in the patient populations. As a result, the
8 SWEDEPAD trial and meta-analysis results are not directly comparable. An updated
9 meta-analysis including the SWEDEPAD trial and all studies in the meta-analysis
10 (Katsanos et al., 2018) shows marginal differences in mortality rates between the
11 paclitaxel-coated and control groups at two years with Bayesian relative risk (RR) 1.39
12 (95% credible interval (CrI) [1.01, 2.39]) and frequentist RR 1.16 (95% confidence
13 interval (CI) [0.99, 1.36]) and differences in mortality rates during the entire follow-up
14 period with Bayesian RR 1.29 (95% CrI [1.01, 1.72]) and frequentist RR 1.13 (95% CI
15 [0.99, 1.28]) under random-effects models. Given the relatively short follow-up thus far
16 in the SWEDEPAD trial (with a mean follow-up of 2.49 years) and the paclitaxel-coated
17 risk being long-term (e.g., 4 or 5 years), the interim results on the risk of paclitaxel-
18 coated devices reported by the SWEDEPAD trial warrant further investigation.

19

1 **1 Introduction**

2 The SWEDEPAD trial¹, which are investigating paclitaxel-coated versus uncoated
3 devices in patients with peripheral artery disease (PAD), was temporarily suspended on
4 December 2018 due to the potential long-term risk of paclitaxel-coated devices reported
5 by a meta-analysis.² An unplanned interim analysis of the SWEDEPAD trial showed no
6 difference in the mortality rate between the paclitaxel-coated and uncoated groups at one
7 year with a hazard ratio (HR) of 1.03 (95% CI [0.77, 1.37]) or during the entire follow-up
8 period with an HR of 1.06 (95% CI [0.92, 1.22]). Based on these results, it was decided
9 to resume enrollment in the SWEDEPAD trial on March 23, 2020. However, Figure 2 of
10 the SWEDEPAD trial publication shows that the cumulative incidence curves of drug-
11 coated devices constantly stayed above those of uncoated either for the overall population
12 or subgroups of chronic limb threatening ischemia or intermittent claudication.¹ The risk
13 of paclitaxel-coated devices is known to be of long term,^{2,3} while the SWEDEPAD trial
14 has so far had a mean follow-up of 2.49 years which is still relatively short for evaluating
15 long-term risk.

17 **2 Methods and Results**

18 **2.1 Baseline Differences in Patient Populations**

19 By pooling the numbers of deaths and patients from all studies included in the meta-
20 analysis, we treat the combined data as a mega-trial,² and compare the differences in
21 mortality between the SWEDEPAD trial¹ and mega-trial. For the paclitaxel-coated group,
22 we found significant differences in the all-cause death rates at one year with relative risk
23 (RR) 4.4 (95% CI [3.2, 6.0]) and during the entire study period with RR 3.7 (95% CI [3.1,

4.5]). For the uncoated group (control), the mortality rate differences between the SWEDEPAD trial¹ and mega-trial were also significant with RR 4.2 (95% CI [3.0, 5.9]) at one year, and RR 5.7 (95% CI [4.5, 7.2]) during the entire study period. All RRs comparing the SWEDEPAD trial¹ and mega-trial² are larger than 3.5 with p-values smaller than 0.0001, which could have attributed to incomparability between the SWEDEPAD trial¹ and the trials included in the meta-analysis². There are significant differences at the baseline in the patient populations between the SWEDEPAD trial and trials in meta-analysis: the former had 35% intermittent claudication (IC) and 65% chronic limb threatening ischemia (CLTI) while the latter had 89% IC and 11% CLTI. CLTI is an advanced stage of PAD. Compared with intermittent claudication, CLTI has a negative prognosis within a year after the initial diagnosis, with a 1-year amputation rate of approximately 12% and mortality rates of 50% at 5 years and 70% at 10 years.⁴ The baseline prognosis difference could be a main cause of observed differences in mortality rates between the studies.

2.2 Updated Meta-Analysis

We conducted an updated meta-analysis which included the SWEDEPAD trial¹ and all studies in the meta-analysis². The number of deaths by two years of the SWEDEPAD trial¹ was estimated by multiplying the estimated two-year cumulative incidence rate and the total number of patients. For each study in the meta-analysis², we took the results with the longest follow-up as those for the entire study period. The R packages ‘meta’ and ‘bayesmeta’ were used to formulate frequentist and Bayesian random-effects models, respectively.

1

2 As shown in Table 1, both frequentist and Bayesian random-effects models demonstrate
3 no difference in one-year all-cause death rates between paclitaxel-coated and uncoated
4 arms, indicating no short-term risk of paclitaxel-coated devices. At two years or during
5 the entire follow-up period, the frequentist random-effects model yields marginally
6 insignificant differences in all-cause death rates with two-year RR 1.16 (95% CI [0.99,
7 1.36], P=0.063), and the entire follow-up RR 1.13 (95% CI [0.99, 1.28], P=0.065).
8 However, the Bayesian random-effects model yields an RR of 1.39 (95% credible
9 interval (CrI) [1.01, 2.39]) at two years and an RR of 1.29 (95% CrI [1.01, 1.72]) during
10 the entire follow-up period, which suggests significant risk of paclitaxel-coated devices
11 with longer-term follow-ups. The posterior probabilities for the death rate of the
12 paclitaxel-coated arm being higher than that of the control arm were around 0.98 at two
13 years and during the entire follow-ups, with Bayes factors larger than 40. This provides
14 strong evidence for the long-term mortality risk of paclitaxel-coated devices.

15

16 **3. Conclusion**

17 The SWEDEPAD trial¹ enrolled 2289 patients, which is about half of the total number of
18 patients included in the meta-analysis². Although one study with such a large sample size
19 and insignificant results was added, the new meta-analysis still yields marginally
20 significant differences in the mortality rates at two years and during the entire follow-up.
21 Moreover, with a mean follow-up of only 2.49 years, the results of the SWEDEPAD trial
22 warrant further investigation, because the risk from paclitaxel-coated devices is long-
23 term.⁵

References

- 1 Nordanstig J, James S, Andersson M, et al. Mortality with paclitaxel-coated devices in peripheral artery disease. *N Engl J Med* 2020;**383**:2538-2546.
- 2 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. *J Am Heart Assoc* 2018;**7**:e011245.
- 3 Beckman JA, White CJ. Paclitaxel-coated balloons and eluting stents: is there a mortality risk in patients with peripheral artery disease? *Circulation* 2019;**140**:1342-51.
- 4 Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. *J Vasc Surg* 2010;**51**:230-41.
- 5 Rocha-Singh KJ, Duval S, Jaff MR, et al. Mortality and paclitaxel-coated devices: an individual patient data meta-analysis. *Circulation* 2020;**141**:1859-69.

Table 1. Relative risk and interval estimates of the meta-analysis including the SWEDEPAD trial¹ and all studies in the meta-analysis².

		Follow-up period		
		One year	Two years	Entire follow-up
Frequentist	Random-effects	1.04 [0.84, 1.28] *	1.16 [0.99, 1.36]	1.13 [0.99, 1.28]
	P value	0.713	0.063	0.065
Bayesian	Random-effects	1.04 [0.77, 1.41]	1.39 [1.01, 2.39]	1.29 [1.01, 1.72]
	Posterior probability of (RR>1)	0.613	0.978	0.980

* Relative risk (RR) with 95% confidence interval (frequentist) or equal-tailed credible interval (Bayesian) in the brackets.